Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 10.6028
- Book/Share 4.2989
- PB 15.6667
- Debt/Equity 2.998
- CurrentRatio 1.5871
- ROIC 0.281
- MktCap 7920157950.0
- FreeCF/Share 5.1391
- PFCF 13.1477
- PE 13.2574
- Debt/Assets 0.6801
- DivYield 0
- ROE 1.4155
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HALO | Goldman | Neutral | Sell | -- | $56 | Dec. 4, 2025 |
| Upgrade | HALO | Leerink Partners | Underperform | Market Perform | -- | $70 | Oct. 14, 2025 |
| Upgrade | HALO | Morgan Stanley | Equal Weight | Overweight | -- | $75 | Aug. 6, 2025 |
| Resumed | HALO | Goldman | -- | Neutral | -- | $55 | July 10, 2025 |
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
Published: December 04, 2025 by: WSJ
Sentiment: Positive
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Read More
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Published: December 04, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany. The Munich Regional Court's 7th Civil Division found that there is imminent infringement for Keytruda SC in Germany regarding one of Halozyme's MDASE™ patents in Europe, European Patent No.
Read More
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Read More
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
What Makes Halozyme Therapeutics (HALO) a New Buy Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier SAN DIEGO , Nov. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™. The …
Read More
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Read More
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
Read More
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Halozyme Just Bought Its Next Decade Of Growth
Published: October 23, 2025 by: Seeking Alpha
Sentiment: Positive
Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for ≤2 mL self-injections, complementing ENHANZE rather than cannibalizing it. Existing partners like Lilly, Argenx, and J&J are already aligned, with first-in-human Hypercon studies expected within 12–15 months.
Read More
Halozyme to Report Third Quarter 2025 Financial and Operating Results
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m.
Read More
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
Read More
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Read More
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, …
Read More
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Read More
5 Biotech Stocks Worth Adding to Your Portfolio Now
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Read More
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Read More
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Read More
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone. Welcome to Morgan Stanley's Global Healthcare Conference.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
Read More
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Read More
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for September 3rd
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Helen I. Torley
- Employees 350